Table 7.

Incremental Utility of Biomarkers Over Clinical Risk Factors and BNP Within Clinical Subgroups

	Composite	LVH_80	LVSD_MILDGR
With MI
NRI	0.580 (0.133, 1.028)	0.834 (0.429, 1.239)	0.276 (−0.161, 0.713)
P Value for NRI	0.018	0.0002	0.220
Without MI
NRI	0.178 (0.081, 0.275)	0.225 (0.124, 0.326)	0.297 (0.096, 0.498)
P Value for NRI	0.0004	0.00002	0.004
≥65 years
NRI	0.084 (−0.075, 0.243)	0.227 (0.066, 0.389)	0.260 (−0.022, 0.541)
P Value for NRI	0.305	0.006	0.073
<65 years
NRI	0.274 (0.156, 0.392)	0.281 (0.154, 0.409)	0.202 (−0.01, 0.413)
P Value for NRI	0.00001	0.00002	0.062
With HTN
NRI	0.246 (0.114, 0.378)	0.306 (0.172, 0.441)	0.270 (0.035, 0.505)
P Value for NRI	0.0003	0.00001	0.025
Without HTN
NRI	0.128 (−0.011, 0.266)	0.173 (0.021, 0.324)	0.112 (−0.132, 0.356)
P Value for NRI	0.073	0.027	0.371

Values represent net reclassification improvement (NRI) and P‐values for comparison between a model including risk factors plus BNP and a model including risk factors, BNP, and novel biomarkers. We did not observe any statistically significant change in the C‐statistic between these models; therefore we did not report data on the C‐statistic. BNP indicates B‐type natriuretic peptide; HTN, hypertension; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; LVSD_MILDGR, mild/greater LVSD.